ArticleJapanese journal of radiology2026
Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO 2018): a two-center retrospective study.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the efficacy and safety of high-dose pelvic radiotherapy combined with chemotherapy, including bevacizumab and immune checkpoint inhibitors (ICI) in patients with stage IVB cervical cancer (CC) based on the 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging system. MATERIALS AND
methodsA retrospective analysis was conducted on 38 patients with stage IVB CC, as classified by the 2018 FIGO cervical cancer staging system, who received pelvic external beam radiotherapy (≥ 40 Gy) with or without brachytherapy and chemotherapy. Data were collected from two centers. The 2-year local control (LC), progression-free survival (PFS), and overall survival (OS) rates were analyzed using the Kaplan-Meier method. Symptom relief, including reductions in genital bleeding and pain from the primary lesion, was assessed. Acute and late adverse events were also evaluated.
resultsThe median follow-up period was 17.5 months. The 2-year LC, PFS, and OS were 82%, 11%, and 47%, respectively. Although the evaluation method has limitations, most patients with genital bleeding and pain from the primary lesion showed improvement in symptoms. Late adverse events of grade ≥ 2 related to both pelvic radiotherapy and bevacizumab included one case of grade 3 gastrointestinal bleeding and two cases of grade 2 fistula.
conclusionThis two-center study demonstrated that high-dose pelvic radiotherapy combined with chemotherapy, including bevacizumab and ICI, may achieve favorable local control and symptom relief in patients with stage IVB CC while maintaining an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.